Shen T, Wei L, Li X, et al. - Given that targeting androgen receptor (AR) pathway may be a potential new treatment approach in metastatic breast carcinomas (BCs) with phenotype of triple negative or low hormonal receptor levels, researchers here assessed AR expression using immunohistochemistry as well as genetic alterations using next generation sequencing. Of 114 metastatic BCs, 37 (32.5%) cases exhibited AR expression and 77 (67.5%) were lacking AR expression. Significantly longer metastatic intervals and overall survivals were observed in patients with AR-positive tumors. Also, a significantly higher rate of PI3CA mutation was found in AR-positive tumors. Overall, findings showed prognostic value of AR expression in this subgroup of metastatic BCs. Different molecular alterations were present between tumors with AR expression and those without AR expression.